Literature DB >> 18464118

Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia.

Claire Villalva1, Nathalie Sorel, Marie-Laure Bonnet, Joëlle Guilhot, Caroline Mayeur-Rousse, François Guilhot, Jean-Claude Chomel, Ali G Turhan.   

Abstract

The murine equivalent of neutrophil gelatinase-associated lipocalin (NGAL) was previously found to be increased by BCR-ABL expression in murine models of chronic myeloid leukemia (CML). Our study evaluates, in CML patients at various clinical stages, the levels of NGAL mRNA in blood samples and protein in sera. A highly significant increase of mRNA expression and protein secretion was shown in patients at diagnosis. The parallel expression of NGAL and BCR-ABL at the early stage of CML process allows us to suggest that NGAL could play an important role in the physiopathology of CML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18464118     DOI: 10.1080/10428190801942360

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Serum neutrophil gelatinase-associated lipocalin and proinflammatory cytokines in pigs with septic versus non-septic acute kidney injury.

Authors:  Hengjin Wang; Miao Zhang; Huijuan Mao; Zhixiang Cheng; Qingyan Zhang; Chunming Jiang; Chen Sun; Lingyun Sun
Journal:  Int Urol Nephrol       Date:  2014-11-25       Impact factor: 2.370

Review 2.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

3.  Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome.

Authors:  E Cakal; M Ozkaya; Y Engin-Ustun; Y Ustun
Journal:  J Endocrinol Invest       Date:  2010-05-28       Impact factor: 4.256

4.  Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness.

Authors:  Sean M Bagshaw; Michael Bennett; Michael Haase; Anja Haase-Fielitz; Moritoki Egi; Hiroshi Morimatsu; Giuseppe D'amico; Donna Goldsmith; Prasad Devarajan; Rinaldo Bellomo
Journal:  Intensive Care Med       Date:  2009-12-03       Impact factor: 17.440

5.  Lipocalin 2: a multifaceted modulator of human cancer.

Authors:  Jiang Yang; Marsha A Moses
Journal:  Cell Cycle       Date:  2009-08-08       Impact factor: 4.534

6.  Lipocalin 2 is required for pulmonary host defense against Klebsiella infection.

Authors:  Yvonne R Chan; Jessica S Liu; Derek A Pociask; Mingquan Zheng; Timothy A Mietzner; Thorsten Berger; Tak W Mak; Matthew C Clifton; Roland K Strong; Prabir Ray; Jay K Kolls
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 7.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

8.  Neutrophil gelatinase-associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta-analysis.

Authors:  Yu Wang; Tingting Zeng
Journal:  Biomed Rep       Date:  2013-03-27

9.  Neutrophil gelatinase-associated lipocalin increases HLA-G(+)/FoxP3(+) T-regulatory cell population in an in vitro model of PBMC.

Authors:  Gaetano La Manna; Giulia Ghinatti; Pier Luigi Tazzari; Francesco Alviano; Francesca Ricci; Irene Capelli; Vania Cuna; Paola Todeschini; Eugenio Brunocilla; Pasqualepaolo Pagliaro; Laura Bonsi; Sergio Stefoni
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.

Authors:  Saverio Candido; Roberta Maestro; Jerry Polesel; Alessia Catania; Francesca Maira; Santo S Signorelli; James A McCubrey; Massimo Libra
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.